Intensive Blood Pressure Reduction in Patients with Increased Cardiovascular Risk with High-Dose Combination Therapy of 160 mg Valsartan plus 25 mg Hydrochlorothiazide. Results of the MACHT II Observational Study: Ergebnisse der MACHT-II-Beobachtungsstudie